Immunotherapy after hematopoietic stem cell transplantation using umbilical cord blood-derived products.
Umbilical cord blood (UCB) is being increasingly used as a source of hematopoietic stem cells (HSC) for transplantation. UCB transplantation (UCBT) has some advantages such as less stringent HLA-matching requirements, fast availability of the graft and reduced incidence and severity of graft-versus-host disease. However, UCBT is also associated with a higher incidence of infection, graft failure, slow engraftment and slow immune reconstitution. UCB is mainly used as a source of HSC; however, it is also rich in immune cells that could be used to treat some of the main complications post-UCBT as well as other diseases, thus implicating the use of UCB for immunotherapy. Here, we aim to describe some of the therapies currently developed that use UCB as a cell source, focusing in particular on regulatory T cells and natural killer cells.
University College London, London, UK.|Anthony Nolan Research Institute, Fleet Road, London, NW3 2QG, UK.
Aurore
A
Saudemont
University College London, London, UK. a.madrigal@ucl.ac.uk.|Anthony Nolan Research Institute, Fleet Road, London, NW3 2QG, UK. a.madrigal@ucl.ac.uk.
J Alejandro
JA
Madrigal
D005312:Fetal Blood / Q000737:chemistry / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D019172:Transplantation Conditioning / Q000379:methods*
Cell therapy; Hematopoietic stem cell transplantation; Natural killer cells; PIVAC 15; Regulatory T cells; Umbilical cord blood